Evidence map›Paper›PMID 40243677›Full record

ArticleInternational journal of molecular sciences2025

Apixaban Inhibits Progression of Experimental Diabetic Nephropathy by Blocking Advanced Glycation End Product-Receptor Axis.

Takanori Matsui, Ami Sotokawauchi, Yuri Nishino, Yoshinori Koga, Sho-Ichi Yamagishi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Takanori MatsuiDepartment of Bioscience and Biotechnology, Fukui Prefectural University, Eiheiji 910-1195, Japan.ORCID 0000-0001-9506-7571
Ami SotokawauchiDepartment of Pediatric Surgery, Kurume University School of Medicine, Kurume 830-0011, Japan.ORCID 0000-0002-4608-9341
Yuri NishinoDepartment of Medicine, Division of Nephrology, Kurume University School of Medicine, Kurume 830-0011, Japan.
Yoshinori KogaDepartment of Pediatric Surgery, Kurume University School of Medicine, Kurume 830-0011, Japan.
Sho-Ichi YamagishiDepartment of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University Graduate School of Medicine, Tokyo 142-8666, Japan.ORCID 0000-0003-0102-0823

Funding

Bristol Myers Squibb, Tokyo, Japan none
6 · The paper itself

Abstract

Diabetes is associated with an increased risk of thromboembolism. However, the effects of apixaban, a factor Xa inhibitor on diabetic nephropathy, remain unknown. Six-week-old Wistar rats received a single 60 mg/kg intraperitoneal injection of streptozotocin to produce a model of type 1 diabetes. Type 1 diabetic and non-diabetic control rats were treated with or without apixaban orally for 8 weeks, and blood and kidneys were obtained for biochemical, real-time reverse transcription-polymerase chain reaction (RT-PCR) and morphological analyses. Although apixaban treatment did not affect glycemic or lipid parameters, it significantly (

Indexed as

Diabetes Mellitus, ExperimentalDiabetic NephropathiesFactor Xa InhibitorsPyrazolesPyridonesReceptor for Advanced Glycation End ProductsAnimalsDisease ProgressionGlycation End Products, AdvancedKidneyMaleRatsRats, WistarapixabanFactor Xa InhibitorsGlycation End Products, AdvancedPyrazolesPyridonesReceptor for Advanced Glycation End ProductsAGEsapixabandiabetic nephropathyRAGE

Identifiers

PMID40243677
PMCPMC11988465

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.